Novel model for basaloid triple-negative breast cancer: Behavior in vivo and response to therapy

Neoplasia (United States)

Volumn 14, Issue 10, 2012, Pages 926-942

  Volk Draper, Lisa D ^a   Rajput, Sandeep ^a   Hall, Kelly L ^a   Wilber, Andrew ^a   Ran, Sophia ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CISPLATIN; CYTOKERATIN 14; CYTOKERATIN 17; CYTOKERATIN 5; CYTOKERATIN 6; DOXORUBICIN; ERLOTINIB; MESSENGER RNA; NEUROPILIN 2; PACLITAXEL; PERIFOSINE; TAXANE DERIVATIVE; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MONOCLONAL ANTIBODY; PROGESTERONE RECEPTOR; TUMOR MARKER; VEGFA PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL CELL CARCINOMA; BREAST CARCINOMA; CANCER GROWTH; CANCER RECURRENCE; CELL PROLIFERATION; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; LYMPH NODE METASTASIS; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH; TUMOR VOLUME; WESTERN BLOTTING; ANIMAL; BREAST TUMOR; CELL MOTION; DISEASE MODEL; ENZYME IMMUNOASSAY; GENETICS; LUNG TUMOR; METABOLISM; METASTASIS; NUDE MOUSE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL MOVEMENT; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PACLITAXEL; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84867815687     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.12956     Document Type: Article

References (73)

1. Jemal A, Siegel R, Xu J, and Ward E (2010). Cancer statistics, 2010. CA Cancer J Clin 60, 277-300.
2. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn RM, Jeffrey SS, et al. (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98, 10869-10874.
3. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, et al. (2004). Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10, 5367-5374.
4. Dawson SJ, Provenzano E, and Caldas C (2009). Triple negative breast cancers: clinical and prognostic implications. Eur J Cancer 45(Suppl 1), 27-40.
5. Dolle JM, Daling JR, White E, Brinton LA, Doody DR, Porter PL, and Malone KE (2009). Risk factors for triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomarkers Prev 18, 1157-1166.
6. Nofech-Mozes S, Trudeau M, Kahn HK, Dent R, Rawlinson E, Sun P, Narod SA, and Hanna WM (2009). Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers. Breast Cancer Res Treat 118, 131-137.
7. Trivers KF, Lund MJ, Porter PL, Liff JM, Flagg EW, Coates RJ, and Eley JW (2009). The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control 20, 1071-1082.
8. Dawood S, Broglio K, Kau SW, Green MC, Giordano SH, Meric-Bernstam F, Buchholz TA, Albarracin C, Yang WT, Hennessy BT, et al. (2009). Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes. J Clin Oncol 27, 220-226.
9. Stead LA, Lash TL, Sobieraj JE, Chi DD, Westrup JL, Charlot M, Blanchard RA, Lee JC, King TC, and Rosenberg CL (2009). Triple-negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Res 11, R18.
10. Mersin H, Yildirim E, Berberoglu U, and Gulben K (2009). Triple negative phenotype and N-ratio are important for prognosis in patients with stage IIIB non-inflammatory breast carcinoma. J Surg Oncol 100, 681-687.
11. Onitilo AA, Engel JM, Greenlee RT, and Mukesh BN (2009). Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 7, 4-13.
12. Heitz F, Harter P, Lueck HJ, Fissler-Eckhoff A, Lorenz-Salehi F, Scheil-Bertram S, Traut A, and du Bois BA (2009). Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. Eur J Cancer 45, 2792-2798.
13. Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, and Narod SA (2009). Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat 115, 423-428.
14. Anders C and Carey LA (2008). Understanding and treating triple-negative breast cancer. Oncology (Williston Park) 22, 1233-1239.
15. Dawood S, Broglio K, Esteva FJ, Yang W, Kau SW, Islam R, Albarracin C, Yu TK, Green M, Hortobagyi GN, et al. (2009). Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol 20, 621-627.
16. Rakha EA and Ellis IO (2009). Triple-negative/basal-like breast cancer: review. Pathology 41, 40-47.
17. Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, El-Sayed ME, Benhasouna A, Brunet JS, Akslen LA, et al. (2009). Triplenegative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 15, 2302-2310.
18. van de Rijn RM, Perou CM, Tibshirani R, Haas P, Kallioniemi O, Kononen J, Torhorst J, Sauter G, Zuber M, Kochli OR, et al. (2002). Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 161, 1991-1996.
19. Sasa M, Bando Y, Takahashi M, Hirose T, and Nagao T (2008). Screening for basal marker expression is necessary for decision of therapeutic strategy for triplenegative breast cancer. J Surg Oncol 97, 30-34.
20. Charafe-Jauffret E, Ginestier C, Monville F, Finetti P, Adelaide J, Cervera N, Fekairi S, Xerri L, Jacquemier J, Birnbaum D, et al. (2006). Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 25, 2273-2284.
21. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, and Perou CM (2006). Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 19, 264-271.
22. Grushko TA, Blackwood MA, Schumm PL, Hagos FG, Adeyanju MO, Feldman MD, Sanders MO, Weber BL, and Olopade OI (2002). Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers. Cancer Res 62, 1481-1488.
23. Armes JE, Trute L, White D, Southey MC, Hammet F, Tesoriero A, Hutchins AM, Dite GS, McCredie MR, Giles GG, et al. (1999). Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer Res 59, 2011-2017.
24. Umemura S, Takekoshi S, Suzuki Y, Saitoh Y, Tokuda Y, and Osamura RY (2005). Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression. Oncol Rep 14, 337-343.
25. Jacquemier J, Ginestier C, Rougemont J, Bardou VJ, Charafe-Jauffret E, Geneix J, Adelaide J, Koki A, Houvenaeghel G, Hassoun J, et al. (2005). Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res 65, 767-779.
26. Sabatier R, Jacquemier J, Bertucci F, Esterni B, Finetti P, Azario F, Birnbaum D, Viens P, Goncalves A, and Extra JM (2011). Peritumoural vascular invasion: amajor determinant of triple-negative breast cancer outcome. Eur J Cancer 47, 1537-1545.
27. Liu HT, Ma R, Yang QF, Du G, and Zhang CJ (2009). Lymphangiogenic characteristics of triple negativity in node-negative breast cancer. Int J Surg Pathol 17, 426-431.
28. Kaplan HG, Malmgren JA, and Atwood M (2009). T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy. Breast J 15, 454-460.
29. Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, et al. (2008). Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26, 1275-1281.
30. Gazdar AF, Kurvari V, Virmani A, Gollahon L, Sakaguchi M, Westerfield M, Kodagoda D, Stasny V, Cunningham HT, Wistuba II, et al. (1998). Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int J Cancer 78, 766-774.
31. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, and Pietenpol JA (2011). Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121, 2750-2767.
32. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, et al. (2006). A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10, 515-527.
33. Chu IM, Michalowski AM, Hoenerhoff M, Szauter KM, Luger D, Sato M, Flanders K, Oshima A, Csiszar K, and Green JE (2011). GATA3 inhibits lysyl oxidase-mediated metastases of human basal triple-negative breast cancer cells. Oncogene, 2017-2027.
34. Murrow LM, Garimella SV, Jones TL, Caplen NJ, and Lipkowitz S (2010). Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome. Breast Cancer Res Treat 122, 347-357.
35. Buchholz S, Seitz S, Schally AV, Engel JB, Rick FG, Szalontay L, Hohla F, Krishan A, Papadia A, Gaiser T, et al. (2009). Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist cetrorelix with growth inhibition. Int J Oncol 35, 789-796.
36. Volk LD, Flister MJ, Bivens CM, Stutzman A, Desai N, Trieu V, and Ran S (2008). Nab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent anti-vascular endothelial growth factor A therapy. Neoplasia 10, 613-623.
37. Volk LD, Flister MJ, Chihade D, Desai N, Trieu V, and Ran S (2011). Synergy of nab-paclitaxel and bevacizumab in eradicating large orthotopic breast tumors and preexisting metastases. Neoplasia 13, 327-338.
38. Li Y, Wang H, Oosterwijk E, Tu C, Shiverick KT, Silverman DN, and Frost SC (2009). Expression and activity of carbonic anhydrase IX is associated with metabolic dysfunction in MDA-MB-231 breast cancer cells. Cancer Invest 27, 613-623.
39. Dolai S, Xu Q, Liu F, and Molloy MP (2011). Quantitative chemical proteomics in small-scale culture of phorbol ester stimulated basal breast cancer cells. Proteomics 11, 2683-2692.
40. Li Q, Chen C, Kapadia A, Zhou Q, Harper MK, Schaack J, and LaBarbera DV (2011). 3D models of epithelial-mesenchymal transition in breast cancer metastasis: high-throughput screening assay development, validation, and pilot screen. J Biomol Screen 16, 141-154.
41. Leibl S and Moinfar F (2005). Metaplastic breast carcinomas are negative for Her-2 but frequently express EGFR (Her-1): potential relevance to adjuvant treatment with EGFR tyrosine kinase inhibitors? J Clin Pathol 58, 700-704.
42. Yamaguchi R, Horii R, Maeda I, Suga S, Makita M, Iwase T, Oguchi M, Ito Y, and Akiyama F (2010). Clinicopathologic study of 53 metaplastic breast carcinomas: their elements and prognostic implications. Hum Pathol 41, 679-685.
43. Singal R, Singh P, Sahu P, Mittal A, Naredi B, and Gupta S (2011). Metaplastic carcinoma of the breast with high grade spindle cell component with osteoid formation-a rare case report. Acta Chir Belg 111, 243-245.
44. Honda M, Saji S, Horiguchi S, Suzuki E, Aruga T, Horiguchi K, Kitagawa D, Sekine S, Funata N, Toi M, et al. (2011). Clinicopathological analysis of ten patients with metaplastic squamous cell carcinoma of the breast. Surg Today 41, 328-332.
45. Guelstein VI, Tchypysheva TA, Ermilova VD, Litvinova LV, Troyanovsky SM, and Bannikov GA (1988). Monoclonal antibody mapping of keratins 8 and 17 and of vimentin in normal human mammary gland, benign tumors, dysplasias and breast cancer. Int J Cancer 42, 147-153.
46. Gusterson BA, Ross DT, Heath VJ, and Stein T (2005). Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Res 7, 143-148.
47. Carey LA (2011). Directed therapy of subtypes of triple-negative breast cancer. Oncologist 16(Suppl 1), 71-78.
48. Fan LZ and Cherian MG (2002). Potential role of p53 on metallothionein induction in human epithelial breast cancer cells. Br J Cancer 87, 1019-1026.
49. Whitehurst B, Flister MJ, Bagaitkar J, Volk L, Bivens CM, Pickett B, Castro-Rivera E, Brekken RA, Gerard RD, and Ran S (2007). Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model. Int J Cancer 121, 2181-2191.
50. Flister MJ, Volk LD, and Ran S (2011). Characterization of Prox1 and VEGFR-3 expression and lymphatic phenotype in normal organs of mice lacking p50 subunit of NF-κB. Microcirculation 18, 85-101.
51. Korsching E, Packeisen J, Agelopoulos K, Eisenacher M, Voss R, Isola J, van Diest PJ, Brandt B, Boecker W, and Buerger H (2002). Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest 82, 1525-1533.
52. Linderholm BK, Hellborg H, Johansson U, Elmberger G, Skoog L, Lehtio J, and Lewensohn R (2009). Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol 20, 1639-1646.
53. Izsvak Z, Ivics Z, and Plasterk RH (2000). Sleeping Beauty, a wide host-range transposon vector for genetic transformation in vertebrates. J Mol Biol 302, 93-102.
54. Luker GD and Luker KE (2008). Optical imaging: current applications and future directions. J Nucl Med 49, 1-4.
55. Hockel M and Vaupel P (2001). Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93, 266-276.
56. Ran S, Volk L, Hall K, and Flister MJ (2009). Lymphangiogenesis and lymphatic metastasis in breast cancer. Pathophysiology 17, 229-251.
57. Hall K and Ran S (2010). Regulation of tumor angiogenesis by the local environment. Front Biosci 15, 195-212.
58. Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, and Jain RK (2011). Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 91, 1071-1121.
59. Carmeliet P (2005). VEGF as a key mediator of angiogenesis in cancer. Oncology 69(suppl 3), 4-10.
60. Hu L, Hofmann J, Zaloudek C, Ferrara N, Hamilton T, and Jaffe RB (2002). Vascular endothelial growth factor immunoneutralization plus paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol 161, 1917-1924.
61. Fox WD, Higgins B, Maiese KM, Drobnjak M, Cordon-Cardo C, Scher HI, and Agus DB (2002). Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer. Clin Cancer Res 8, 3226-3231.
62. Sirohi B and Smith K (2008). Bevacizumab in the treatment of breast cancer. Expert Rev Anticancer Ther 8, 1559-1568.
63. Lobo C, Lopes G, Silva O, and Gluck S (2007). Paclitaxel albumin-bound particles (abraxane) in combination with bevacizumab with or without gemcitabine: early experience at the University of Miami/Braman Family Breast Cancer Institute. Biomed Pharmacother 61, 531-533.
64. Wong SW, Tiong KH, Kong WY, Yue YC, Chua CH, Lim JY, Lee CY, Quah SI, Fow C, Chung C, et al. (2011). Rapamycin synergizes cisplatin sensitivity in basal-like breast cancer cells through up-regulation of p73. Breast Cancer Res Treat 128, 301-313.
65. Morgan K, Meyer C, Miller N, Sims AH, Cagnan I, Faratian D, Harrison DJ, Millar RP, and Langdon SP (2011). GnRH receptor activation competes at a low level with growth signaling in stably transfected human breast cell lines. BMC Cancer 11, 476.
66. Jonsson G, Staaf J, Olsson E, Heidenblad M, Vallon-Christersson J, Osoegawa K, de Jong JP, Oredsson S, Ringner M, Hoglund M, et al. (2007). High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization. Genes Chromosomes Cancer 46, 543-558.
67. Bjorndahl MA, Cao R, Burton JB, Brakenhielm E, Religa P, Galter D, Wu L, and Cao Y (2005). Vascular endothelial growth factor-a promotes peritumoral lymphangiogenesis and lymphatic metastasis. Cancer Res 65, 9261-9268.
68. Dadiani M, Kalchenko V, Yosepovich A, Margalit R, Hassid Y, Degani H, and Seger D (2006). Real-time imaging of lymphogenic metastasis in orthotopic human breast cancer. Cancer Res 66, 8037-8041.
69. Ejlertsen B, Jensen MB, Rank F, Rasmussen BB, Christiansen P, Kroman N, Kvistgaard ME, Overgaard M, Toftdahl DB, and Mouridsen HT (2009). Population-based study of peritumoral lymphovascular invasion and outcome among patients with operable breast cancer. J Natl Cancer Inst 101, 729-735.
70. Kwon Y, Ro J, Kang HS, Kim SK, Hong EK, Khang SK, Gong G, and Ro JY (2011). Clinicopathological parameters and biological markers predicting nonsentinel node metastasis in sentinel node-positive breast cancer patients. Oncol Rep 25, 1063-1071.
71. Williams CS, Leek RD, Robson AM, Banerji S, Prevo R, Harris AL, and Jackson DG (2003). Absence of lymphangiogenesis and intratumoural lymph vessels in human metastatic breast cancer. J Pathol 200, 195-206.
72. Zumsteg A, Baeriswyl V, Imaizumi N, Schwendener R, Ruegg C, and Christofori G (2009). Myeloid cells contribute to tumor lymphangiogenesis. PLoS One 4, e7067.
73. Hall KL, Volk-Draper LD, Flister MJ, and Ran S (2012). New model of macrophage acquisition of the lymphatic endothelial phenotype. PLoS One 7, e31794.